Adam is the Managing Partner of Anterra Capital, an independent growth capital fund that invests in fast growing companies that transform the way we produce, move and consume food. Anterra was founded in 2013 from a spin-out of Rabobank’s proprietary venture capital fund, Rabo Ventures. The fund is backed by Rabobank, a global leader in food & agriculture financing; and Moonray Investors, the proprietary investment arm of Fidelity International. Through its alliance with Rabobank and Moonray, Anterra offers portfolio companies industry-leading food & agriculture knowledge and investment experience, along with access to a strong, combined global network. Adam has over 14 years private equity and venture capital experience. Earlier in his career Adam worked as a management consultant with Bain & Co. Adam holds an MBA degree from Cambridge University, England and a Bachelors Degree in Law and a Bachelors Degree in Commerce from the University of Adelaide, Australia.
Sharon recently joined Kaiima Agri-Biotech to set up and lead their US operations. Sharon studied Agriculture and Biochemistry at the University of Missouri, Columbia. After a few years in academia, Sharon joined Monsanto, where she held positions in R&D, Regulatory Science & Affairs, Licensing and M&A, Specialty and New Crops, Field Operations and other crop-focused businesses. After leaving Monsanto, Sharon was an independent consultant and spent three years at a start-up, Chlorogen Inc. She subsequently held positions as Director of International Programs and Assistant Director of Technology Management at the Donald Danforth Plant Science Center. Sharon then joined Dow AgroSciences to establish an Agronomic Traits pipeline and to lead out-licensing efforts related to the EXZACT™ Precision Technology (zinc fingers in plants). She was instrumental in developing Dow’s licensing function and led transactions across the business, including biotechnology traits, enabling technologies and crop protection. In last role, Sharon led the Venture Capital investment strategy and related deals for Dow AgroSciences.
Dan has over 25 years of experience in the life sciences and venture capital industry. Prior to joining BioGenerator in 2009, he was a Managing Director at Prolog Ventures in St. Louis. Prior to that Dan spent 7 years with Mason Wells Biomedical Fund as a Managing Director where he was responsible for all aspects of investment activities. While at Mason Wells, he served as a member of the Board of Directors of several portfolio companies including Gala Biotech, Mezzia, OpGen, Deltanoid Pharmaceuticals and ZyStor Therapeutics. Dan is actively involved in the venture capital community on a regional and national level. He served on the Board of Directors of the National Venture Capital Association (NVCA) and has testified before the US Congress on behalf of the NVCA. Dan received a Bachelor's in Biology from Iowa State University, and has completed some graduate course work in Finance, Accounting and Marketing at Winona State University.
Jim is the Managing Principal of MacroGain Partners, an Indiana firm focused on structuring venture and private equity investments in companies in the agricultural, food, and green energy industries and providing related strategic planning and management consulting services. Jim works with institutional investors, private equity firms, and venture capital investors to identify and/or evaluate agricultural investment targets. Jim has over 30 years of direct agrifood and related markets experience; he holds a BS in Agronomy from Purdue University and earned his MS and PhD in Soil Chemistry from the University of Arizona. He provides strategic counsel to dozens of agribusinesses, from start-ups to major multinationals, and frequently provides strategic technology and market sector assessments to both private equity and venture capital investors.
Jonathan’s focus at ARPA-E is in advanced biotechnology applications for biofuels and the production of biologically-based chemical feedstocks. Prior to joining ARPA-E, Jonathan was a biotechnology consultant focusing on realizing value from novel technologies, products, and commercial strategies in the life sciences. He is the founder of two companies and has worked extensively for corporate, venture, and government clients. Before entering consulting, he played seminal roles with two venture-backed startup companies, Pharmacopeia and ActivX Biosciences, which is now a division of Kyorin Pharmaceuticals. Jonathan received his BS in Chemistry from Rensselaer Polytechnic Institute, his MBA from the University of California, San Diego, and his PhD from Harvard University - where he worked for Jeremy R. Knowles on the energetics of enzymatic catalysis. Jonathan also conducted post-doctoral work at MIT with Paul Schimmel, focusing on protein structure, function and folding.
Philippe is Managing Director of HighQuest Partners leading the Global Food & Agribusiness Practice at their St. Louis, Missouri office. He has more than 20 years of experience in senior leadership positions with global companies in the agro-industrial and value-added food chain as well as in private equity investing. Prior to joining High Quest Partners, Philippe was a Principal at Vanikoro Advisory LLC where he advised clients on their financial and global expansion strategies. Previously, as Director of Business Development for Bunge North America, Inc., he was responsible for the company’s efforts to expand its industrial operations into Mexico and the Caribbean Basin, biotech and e-commerce initiatives and public relations/corporate communications (before and after Bunge’s successful IPO in 2001). Philippe received an MBA from The Darden School of Business at The University of Virginia in Charlottesville, VA and a BA from Trinity College, in Hartford, CT.
Kirk is the CEO of SG Biofuels, a sustainable plant oil company with operations in San Diego, CA and Latin America. SG Biofuels specializes in the development of Jatropha as a low cost, sustainably produced oil that can be used for a variety of bio-based materials including biodiesel and feedstock substitutes for the petrochemical and jet fuel industries. Kirk has a successful track record developing sustainable, for-profit projects, and extensive experience in both established and start-up companies. As President of Green Millennium, Kirk raised over $100M in private equity and successfully built and scaled a sustainable forestry company from start-up to over 100 employees. Kirk has held senior and executive management positions for 3Com, ArrowPoint Communications, Cisco Systems and Green Millennium. He was instrumental in creating Cisco's global security sales strategy, resulting in Cisco surpassing $1B in security sales. Kirk holds an MBA from Pepperdine University and is fluent in Spanish and German.
Dr. Philippe Herve is Global Head of R&D Alliance Management at Bayer CropScience, in charge of managing a global team leading partnerships and relations with investors for agriculture innovation worldwide across the range of products and expertise in the company. Philippe received his Ph.D. in biotechnology in Toulouse, France, with expertise in both chemistry and plant biology. He has more than 15 years of experience in Ag-industry, working across early stage company, international research organizations and multi-national companies in Europe, Asia and USA and has been in charge of international projects and establishing partnerships across a range of projects.
Mark Kahn is the co-founder of Omnivore Partners, a venture capital firm, based in India, investing in startups that are developing breakthrough technologies for food and agriculture. Mark is a Director for multiple Omnivore-backed startups, including Skymet, FrontalRain, Arohan Foods, Eruvaka, and YCook.
Previously, Mark was the Executive Vice President (Strategy & Business Development) at Godrej Agrovet, one of India's foremost diversified agribusiness companies. At Godrej Agrovet, Mark was responsible for corporate strategy, M&A, R&D, and new business incubation.
Earlier in his career, Mark worked for Syngenta and PFM. He earned a BA (Honors) from the University of Pennsylvania and an MBA from Harvard Business School, where he graduated as a Baker Scholar.
Rob is CEO of AgFunder, an investment marketplace platform for the $6.4 Trillion dollar agriculture industry. Rob has been published in the Harvard Business Review, Financial Post, Seeking Alpha, and twice in Nature journals. Rob has been invited to speak at global conferences on agriculture, technology, and capital raising. He has given seminars at the USDA, been featured in Forbes and Reuters, judged for the National Ag Innovation Prize, and held a committee member position for the Ag Innovation Showcase; the world’s leading AgTech conference. Rob has five degrees, spanning Philosophy, Computer Science, and Computational Biology, including a PhD from Yale University.
Sr. VP of Research
Archer Daniels Midland Company
Sr. VP of Research
Archer Daniels Midland Company
Mark joined Archer Daniels Midland Company in 1980. Mark Matlock was appointed Senior Vice President-Research Division where he directs food ingredient research. He holds a BS in Chemistry from Millikin University and a MS in Polymer Chemistry from the University of Akron. Prior to his current appointment, Mark served as an Analytical Chemist, Manager-Process Development, Laboratory Manager-ADM BioProducts and Director-Food Applications. Mark is author or co-author of nine US patents, two of which relate to an analytical instrument (OSI) that measures the oxidative stability of vegetable oils. He has conducted research that has led to new soy protein isolates for ADM. He has managed research efforts that led the introduction of trans free fats for margarines and shortenings via a novel enzymatic rearrangement technology. In addition, Mark was elected president of the American Oil Chemists’ Society for 2003-2004 and in 2007 was honored as an AOCS Fellow.
Ron has 26 years of experience in bringing new technologies and products to market. During this time he has led R&D for major corporations in agricultural chemicals, field crop and vegetable genetics and breeding, animal health, novel foods and industrial materials. His successful projects include planning and conducting the world's first field trial of a genetically engineered crop trait in 1986, development and launch of one of the first insect and herbicide resistant corn hybrids in 1996, and introduction of a trans-fat free canola oil. Prior to forming MidPoint, Ron spent two years as an executive-on-loan writing an economic development plan which the State of Indiana adopted for its food and agricultural sectors. As Global Leader of Biotechnology at Dow AgroSciences, Ron led the expansion of its biotechnology research and development program. Ron holds a PhD from the University of California, Berkeley in plant cell biology, and a bachelor's degree from the University of Wisconsin, Milwaukee in plant physiology.
Pat Morand, President of Open Prairie Ventures, an Illinois-based venture fund, serves as managing director of the Southwest Michigan First Life Science Fund, headquartered in Kalamazoo, Michigan.
In his management advisory role, Pat is responsible for sourcing all potential investments, leading them through the Southwest Michigan First Life Science Fund's stringent due diligence process and overseeing the fund’s portfolio company management teams. Pat was a three-time chief executive officer in the biologics industry; vice president of Commercial Operations for Genesis Therapeutics; executive vice president of Sequitor Medical Technologies; and executive in residence of the Pittsburgh Life Sciences Greenhouse, a public/private investor in regional life sciences companies where he provided executive support to over 65 companies, representing $100 million of investment and 121 employees.
Pat is a graduate of The Athenaeum of Ohio with a Bachelor of Arts Degree in Philosophy.
Bob runs AndMore Associates, LLC, an independent global business development and consulting firm focused on the nexus of agriculture, energy, and the environment, and building partnerships. Current clients include the Larta Institute and other organizations in the agriculture, cleantech, and energy sectors. As immediate past president of The Sulphur Institute (TSI), Bob led the successful promotion and growth of sulphur as a viable investment and commercial product in agricultural and industrial markets worldwide. The partnerships he built in China helped to stimulate growth of Chinese sulphur imports from zero to nearly ten million tons, now more than a $1 billion market. In India, the initiatives he created and executed built the platform for commercial development of a $2 million ton sulphur fertilizer market. Bob has a BS in Plant Science from Rutgers University and an MS in Agronomy from Pennsylvania State University.
Ag Biotech Business Development
Pioneer Hi-Bred International, Inc.
Ag Biotech Business Development
Pioneer Hi-Bred International, Inc.
Mat is Director of Ag Biotech Business Development at Pioneer Hi-Bred, a DuPont business. The focus of the Ag Biotech BD group is on acquisition and integration of technology into DuPont's Ag biotech portfolio, the enablement and support of research scale, and on the leveraging of technology developed by DuPont scientists into adjacent spaces. Mat has previously occupied a variety of functions within Pioneer, including as a research scientist, principal investigator and operations manager, before taking on strategic and development responsibilities in the business development group and the Global Product Strategy team. Mat has also served in various capacities for Verdia, Inc., Maxygen, Inc., the University of California, and the Swiss National Foundation for Scientific Research. Mat has a PhD in Biology from the University of Lausanne, and an MBA from California State University at Hayward. He is the author of numerous peer-reviewed scientific articles and several patents.
Derek Norman is Managing Director at Syngenta Ventures, the corporate venture capital group of Syngenta. Syngenta Ventures is responsible for investing in and managing a portfolio of companies that can provide strategic value and financial returns for Syngenta. Prior to joining Syngenta Ventures, Derek was an Associate at Hatteras Venture Partners, a life science-focused venture capital firm with $120 million under management. Derek also spent three years at Dean & Co., a strategy consulting firm located in Washington, DC Derek received a PhD in Chemistry and Chemical Biology from Harvard University. There, his thesis work focused on using chemistry, biochemistry and protein crystallography to study the chemical mechanism of DNA repair processes. Derek received a BS in Chemistry from Stanford University.
VP, Business Development
Benson Hill Biosystems
VP, Business Development
Benson Hill Biosystems
Andy has 20 years of experience in plant biotechnology and 12 years of experience in international technology scouting and acquisition. He studied biology and received his PhD from the University of Bayreuth in plant biochemistry and molecular biology. He was PostDoc in Lothar Willimitzer's lab at the Max-Planck-Institute in Potsdam and joined BASF in 1999, where he worked on the production of polyunsaturated fatty acids in oilseeds. From 2003 to 2014, he worked in the field of technology scouting and research collaborations at BASF Plant Science. He was responsible for several international research programs, bilateral collaborations and licenses in Europe, Asia and Americas and has an excellent academic and industrial network in the agricultural solutions field. Early September 2014 he joined Benson Hill Biosystems, a start-up company aiming to increase crop productivity through increased photosynthetic efficiency
David currently leads Monsanto’s Biotechnology Prospecting Team. The Prospecting Team continuously looks for innovative technologies that will help build, extend, and support the Monsanto technology portfolio. From 1999 to 2007, David worked with Renessen LLC as VP of Product Development & Technology where he was responsible for leading the technology, product development and regulatory science functions for Renessen. From 1987 to 1999, he was with Agracetus, Inc. in R&D, and Project Leadership positions. David received his PhD from Rice University in microbial gene expression, and did a NSF Postdoctoral Fellowship at Harvard University.